|
Published by: Global Industry Analysts
Published: Jul. 1, 2006 - 187 Pages
Table of Contents
- I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
- II. EXECUTIVE SUMMARY
- 1. Market Overview
- Biogenerics Spell Opportunities
- Patent Expiration of Biotech Medicines Paves Way for New Generation Biogenerics
- Patent Expiration of Major Biotechnology Products before 2007
- Market Structure
- Potential Key Competitors in the Biogenerics Space
- Entry Barriers for Biogenerics
- Comparison of Entry Barriers for Biogenerics in Select Global Markets
- Is Commercialization of Biogenerics Possible?
- Will Biopharmaceutical Market Witness Intense Competition from Generic Firms?
- Branded Vs Generics Drugs - The Debate Continues
- Growth Impediments
- Heavy Investment
- Shortage of Manufacturing Capacity
- Lack of Clear Regulatory Mechanism
- Overview of Select Markets
- United States
- Biogenerics to Exhibit Slow Start
- Europe
- Australia
- India - Emerging Player in the Biogeneric Market
- 2. Trends and Issues
- US FDA Under Pressure
- Entry Barriers Limit Competition in Biogenerics Market
- Bend the Rule or Not - Authorities in Dilemma
- Biogenerics Market Gains Support from Other Institutions
- Generic Drug Producers Adopt “Evergreening” Concept
- Biogenerics Need to Conform to the Production Norms of Original Products
- 3. Drug Approval Process in US and Europe
- Bioequivalence Tests - Mandatory Requirement for Generics
- Approval Process in the US
- Hatch Waxman Act and FDA Approval Process
- ANDA Review Process
- Generic Exclusivity
- 30-Month Stay Period
- 180-Days Exclusivity Period7
- Time Period for Generic Approval
- Approval Process in Europe
- Generic Companies Face Strict Regulations for Approval
- Data Exclusivity
- 4. Product Overview
- What are Biogenerics?
- Biogenerics - Generic Version of Biopharmaceuticals
- Biopharmaceuticals
- Biogenerics Versus Conventional Generics
- Manufacturing Process of Biogenerics - A Debatable Issue
- 5. Recent Industry Activity
- Teva Acquires IVAX Corporation
- Biopartners Bags EU Marketing Approval for Valtropin
- Sandoz Bags EC Marketing Approval for Omnitrope
- Omnitrope Receives US FDA Approval
- Biocon Limited Partners with Vaccinex Inc
- Novartis Pockets Hexal AG
- Mayne’s Pharma Division Collaborates with Pliva
- Clinigene Initiates Clinical Trials on Biocon’s EGFR Monoclonal Antibody
- Barr Laboratories Signs Agreement with Pliva for Developing G-CSF
- Pliva Croatia Bags Approval for Biogeneric EPO
- Teva Pharmaceutical Industries Acquires SICOR
- Biocon Launches Bio-Insulin
- Cipla in Strategic Alliance with Dongbao Pharmaceutical Company Ltd
- Crucell N.V. Signs a Licensing Agreement with Gene Medicine Japan Inc
- 6. Focus on Select Players
- Biocon Limited (India)
- BioPartners (Switzerland)
- BioGeneriX AG (Germany)
- Cangene Corporation (Canada)
- Cipla Ltd. (India)
- Dr. Reddy's Laboratories (India)
- GeneMedix (UK)
- LG Life Sciences (Korea)
- Pliva d.d. (Croatia)
- Ranbaxy Laboratories Limited (India)
- Sandoz International GmbH (Germany), a Unit of Novartis
- Stada Arzneimittel (Germany)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Teva Pharmaceuticals USA (USA)
- Wockhardt Limited (India)
- 7. Global Market Perspective
- Table 1: Worldwide Market for Biogenerics - Market Projections for US, Europe and Rest of World with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
- Table 2: Worldwide 6-Year Perspective for Biogenerics - Percentage Breakdown of Dollar Sales for US, Europe and Rest of World for Years 2007, 2010 & 2013 (includes corresponding Graph/Chart)
- III. COMPETITION
- 1. Anhui Anke Bio Tech (China)
- 2. Barr Laboratories, Inc. (USA)
- 3. Bharat Biotech International Limited (India)
- 4. Biocon India Limited (India) Table 3: Annual Sales Analysis: 2004-2005 (In INR million) Clinigene (India)
- 5. Biogenerics GmbH (Germany)
- 6. Biogenerics Pharma (USA)
- 7. BiogeneriX AG (Germany)
- 8. Biopartners (Switzerland)
- 9. Cangene Corporation (Canada)
- Table 4: Nine Months Sales Analysis: 2005-2006 (Nine Months Ended, April) (In Can$ million)
- Table 5: Nine Months Sales Analysis by Quarter: 2005- 2006 (Nine Months Ended, April) (In Can$ million)
- Table 6: Annual Sales Analysis: 2003-2005 (In Can$ million)
- Table 7: Annual Sales Analysis by Geographic Region: 2004-2005 (In Can$ million)
- 10. CIGB (Cuba)
- 11. Cipla Ltd. (India)
- Table 8: Annual Sales Analysis: 2003-2005 (In INR billion)
- Table 9: Annual Sales Analysis by Quarter: 2004-2005 (In INR billion)
- 12. Crucell NV (The Netherlands)
- Table 10: First Quarter Sales Analysis: 2005-2006 (In million)
- Table 11: Annual Sales Analysis: 2004-2005 (In million)
- Table 12: Annual Sales Analysis by Geographic Region: 2004-2005 (In million)
- 13. Dr. Reddy's Laboratories Ltd. (India)
- Table 13: Annual Sales Analysis: 2004-2006 (In INR billion)
- Table 14: Annual Sales Analysis by Segment: 2004-2005 (In INR billion)
- Table 15: Annual Sales Analysis by Geographic Region: 2004-2005 (In INR billion)
- 14. Dragon Pharmaceuticals, Inc. (USA)
- 15. Eli Lilly And Company (USA)
- Table 16: First Quarter Sales Analysis: 2005-2006 (In US$ million)
- Table 17: First Quarter Sales Analysis by Segment: 2005-2006 (In US$ million)
- Table 18: First Quarter Sales Analysis by Product: 2005-2006 (In US$ million)
- Table 19: Annual Sales Analysis: 2003-2005 (In US$ Billion)
- Table 20: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)
- Table 21: Annual Sales Analysis by Product: 2004-2005 (In US$ million)
- Table 22: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
- 16. Ferring Pharmaceuticals (USA)
- 17. Gene Medicine Japan, Inc. (Japan)
- 18. GeneMedix PLC (UK)
- 19. Inno Biologics Sdn. Bhd. (Malaysia)
- 20. Insight Biopharmaceuticals Ltd. (Israel)
- 21. Intas Pharmaceuticals Ltd. (India)
- 22. LG Life Sciences (Korea)
- 23. Mayne Pharma PLC (UK)
- 24. Merck KGAA (Germany)
- Table 23: Annual Sales Analysis: 2003-2005 (In million)
- Table 24: Annual Sales Analysis by Segment: 2004-2005 (In million)
- 25. Microbix Biosystems, Inc. (Canada)
- Table 25: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
- Table 26: Annual Sales Analysis: 2004-2005 (In US$ million)
- Table 27: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
- 26. Migenix, Inc. (Canada)
- Table 28: Annual Sales Analysis: 2003-2005 (In US$ million)
- Table 29: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
- 27. Momenta Pharmaceuticals, Inc. (USA)
- Table 30: First Quarter Sales Analysis: 2005-2006 (In US$ million)
- Table 31: Annual Sales Analysis: 2003-2005 (In US$ million)
- 28. Neose Technologies, Inc. (USA)
- Table 32: First Quarter Sales Analysis: 2005-2006 (In US$ million)
- Table 33: Annual Sales Analysis: 2003-2005 (In US$ million)
- Table 34: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
- Table 35: First Quarter Sales Analysis: 2005-2006 (In US$ million)
- Table 36: First Quarter Sales Analysis by Segment: 2005-2006 (In US$ million)
- Table 37: Annual Sales Analysis: 2003-2005 (In US$ million)
- Table 38: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)
- Table 39: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
- Sandoz International GmbH (Germany)
- Sandoz, Inc. (USA)
- 30. Novo Nordisk A/S (Denmark)
- Table 40: Annual Sales Analysis: 2003-2005 (In DKK million)
- Table 41: Annual Sales Analysis by Segment: 2004-2005 (In DKK million)
- Table 42: Annual Sales Analysis by Geographic Region: 2004-2005 (In DKK million)
- 31. Pfizer, Inc. (USA)
- Table 43: Annual Sales Analysis: 2003-2005 (In US$ billion)
- 32. Pliva D.D. (Croatia)
- Table 44: Annual Sales Analysis: 2003-2005 (In US$ million)
- Table 45: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)
- Table 46: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
- 33. Ranbaxy Laboratories Ltd. (India)
- Table 47: First Quarter Sales Analysis: 2004-2005 (In INR billion)
- 34. Savient Pharmaceuticals, Inc. (USA)
- Table 48: First Quarter Sales Analysis: 2005-2006 (In US$ million)
- Table 49: Annual Sales Analysis: 2004-2005 (In US$ million)
- Table 50: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
- 35. Shantha Biotechnics Limited (India)
- 36. Shenyang Sunshine Pharmaceutical Co., Ltd. (China)
- 37. Stada Arzneimittel AG (Germany)
- Table 51: Annual Sales Analysis: 2003-2005 (In million)
- Table 52: Annual Sales Analysis by Segment: 2004-2005 (In million)
- Table 53: Annual Sales Analysis by Geographic Region: 2004-2005 (In million)
- 38. Teva Pharmaceutical Industries Ltd. (Israel)
- Table 54: First Quarter Sales Analysis: 2005-2006 (In US$ billion)
- Table 55: Annual Sales Analysis: 2003-2005 (In US$ billion)
- Teva Pharmaceuticals (USA)
- Sicor, Inc. (USA)
- 39. Vaccinex, Inc. (USA)
- 40. Wockhardt Ltd. (India)
- Table 56: Annual Sales Analysis: 2003-2005 (In INR billion)
- 41. Zenotech Laboratories Ltd. (India)
- Table 57: Annual Sales Analysis: 2003-2005 (In INR million)
- 42. Zydus Cadila (India)
- Table 58: Annual Sales Analysis: 2004-2005 (In INR million)
AbstractThis report analyzes the worldwide markets for Biogenerics in US$ Million. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual forecasts are provided for each region for the period of 2007 through 2013. The report profiles 42 companies including many key and niche players worldwide such as Biocon Limited, BioPartners, BioGeneriX AG, Cangene Corporation, Cipla Ltd., Dr. Reddy's Laboratories, GeneMedix, LG Life Sciences, Pliva d.d., Ranbaxy Laboratories Limited, Sandoz International GmbH, Stada Arzneimittel, Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals USA, and Wockhardt Limited. Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location. Adobe Acrobat Reader 7.0 is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.
Titles available via "online download" are not affected by this and are still delivered to your personal library immediately.
Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
|
About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.
© MarketResearch.com 2008
|